Evaluation of Combined Biomarkers for Tumor Response to Immunotherapy (I/O) in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

被引：0
|
作者：
Ramdani, H. [1 ]
Falk, M. [2 ]
Schatz, S. [2 ]
Tiemann, M. [2 ]
Heukamp, L. [2 ]
Schuuring, E. [3 ]
Groen, H. [3 ]
Griesinger, F. [4 ]
机构：
[1] Carl Von Ossietzky Univ Oldenburg, Innere Med Onkol, Oldenburg, Germany
[2] Hamatopathol Hamburg, Hamburg, Germany
[3] Univ Med Ctr Groningen, Groningen, Netherlands
[4] Carl von Ossietzky Univ Oldenburg, Pius Hosp, Dept Hematol & Oncol, Med Campus, Oldenburg, Germany
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
NSCLC; Immune Checkpoint Inhibitors; tumor mutational burden;
D O I：
10.1016/j.jtho.2019.08.1568
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.04-63
引用
收藏
页码：S732 / S733
页数：2
相关论文
共 50 条
  • [41] A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC).
    Kim, Han Sang
    Cho, Byoung Chul
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [42] Circulating Biomarkers of Frailty Are Associated with a Poor Prognosis in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
    Wyatt, Nicola
    Hogarth, Linda
    Turner, Dianne
    Patterson, Miranda
    Jamieson, David
    Black, Fiona
    Hutton, Claire
    Mulvenna, Paula
    Simmons, Tim
    Bradshaw, Alexander
    Kolenda, Claire
    Parker, Craig
    Martin-Ruiz, Carmen
    Greystoke, Alastair
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S829 - S830
  • [43] Immunotherapy in previously treated non-small cell lung cancer (NSCLC)
    Leal, Ticiana A.
    Ramalingam, Suresh S.
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S422 - S432
  • [44] Immunotherapy Beyond Progression for Patients with Advanced Non-Small Cell Lung Cancer
    Ge, X.
    Zhang, Z.
    Yan, X.
    Zhang, F.
    Yuan, F.
    Han, X.
    Huang, Z.
    Ma, J.
    Wang, L.
    Tao, H.
    Li, X.
    Zhang, S.
    Zhi, X.
    Hu, Y.
    Wang, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S641 - S642
  • [45] The use of immunotherapy in older patients with advanced non-small cell lung cancer
    Tagliamento, Marco
    Frelaut, Maxime
    Baldini, Capucine
    Naigeon, Marie
    Nencioni, Alessio
    Chaput, Nathalie
    Besse, Benjamin
    CANCER TREATMENT REVIEWS, 2022, 106
  • [46] Immunotherapy beyond progression in patients with advanced non-small cell lung cancer
    Ge, Xiangwei
    Zhang, Zhibo
    Zhang, Sujie
    Yuan, Fang
    Zhang, Fan
    Yan, Xiang
    Han, Xiao
    Ma, Junxun
    Wang, Lijie
    Tao, Haitao
    Li, Xiaoyan
    Zhi, Xiaoyu
    Huang, Zhiyue
    Hofman, Paul
    Prelaj, Arsela
    Banna, Giuseppe Luigi
    Mutti, Luciano
    Hu, Yi
    Wang, Jinliang
    TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (06) : 2391 - 2400
  • [47] Early prediction of non-response to immunotherapy by a combined serum tumor marker model in non-small cell lung cancer patients
    Schuurbiers, M.
    Van Delft, F.
    Koffijberg, H.
    Burgers, S.
    IJzerman, M.
    Van Rossum, H.
    Van den Heuvel, M.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1036 - S1036
  • [48] Response to chemotherapy as a predictor of survival in advanced non-small cell lung cancer (NSCLC)
    Soussi, Ghassen
    Racil, Hajer
    Bacha, Saoussen
    Rouhou, Sana Cheikh
    Zidi, Asma
    Ayadi, Aida
    Chaouch, Nawel
    Chabbou, Abdellatif
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [49] Pathological evaluation of tumor infiltrating lymphocytes and the benefit of nivolumab in advanced non-small cell lung cancer (NSCLC)
    Gataa, I.
    Mezquita, L.
    Auclin, E.
    Le Moulec, S.
    Alemany, P.
    Kossai, M.
    Masse, J.
    Caramella, C.
    Masip, J. Remon
    Lahmar, J.
    Ferrara, R.
    Gazzah, A.
    Soria, J-C.
    Planchard, D.
    Besse, B.
    Adam, J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [50] The importance of response to chemotherapy in advanced squamous non-small cell lung cancer (NSCLC).
    Hirsh, Vera
    Wan, Yin
    Whiting, Scott
    Ong, Teng Jin
    Botteman, Marc
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345